NewsBite

Biotech

Advertisement
Melbourne-based Nathan Smith will bring his extensive commercial, operation and strategic experience in developing stem cell therapies to his new role as chief executive officer at biotech company NeuroScientific Biopharmaceuticals.

Strategic CEO hire to drive NeuroScientific stem cell therapy release

NeuroScientific Biopharmaceuticals has made a second heavy-hitting appointment, with Melbourne-based exec Nathan Smith bringing his stem cell therapy nous as CEO.

  • James Pearson

Latest

Iris van Herpen at Paris Haute Couture Week. The Bioluminescent dress is made from living algae.

‘Collaborating with nature’: Designer debuts living dress in Paris runway show

Dutch designer Iris van Herpen harnessed bioluminescent algae to create a living dress. How long will the algae ultimately live after the runway? “No one knows!”

  • Vanessa Friedman
Yat-Gai Au’s net worth has soared.

This mysterious company has never sold a single product. Its founder is now worth $51 billion

A company that aims to treat neurological conditions such as ADHD and autism has made a dizzying share price surge without a single sale. It has made its founder very rich.

  • Angel Adegbesan and Dylan Sloan
Monash IVF is Australia’s second biggest fertility clinics group with an estimated 25.3 per cent market share.

The collateral damage from Monash IVF’s colossal embryo bungles

Monash IVF hasn’t just undermined its own reputation and customer confidence; it must result in a confidence wobble for the entire industry.

  • Elizabeth Knight
Scientist Hugh Goold has completed the final stage of an international effort to create a synthetic yeast genome.

Hugh once delivered cheese to the Queen. Now he’s built the key to synthetic life

The first-ever synthetic multicellular organism is ready to come to life after a Sydney breakthrough 10 years in the making.

  • Angus Dalton
CSL has seen lower vaccination rates in the US, which hit sales of its flu shots.

Falling vaccination rates in Trump’s America hit Australian giant

CSL’s profits have taken a hit from Americans’ reluctance to get vaccinated, sending its shares downward.

  • David Swan
Advertisement
This week’s Bulls N’ Bears ASX Runner of the Week is… Bio-Gene Technology.

ASX Runners of the Week: Bio-Gene, Alterity, Aston & Canterbury

This week’s ASX Bulls N’ Bears Runner of the Week is… Bio-Gene Technology. The company’s shares leapt after revealing it scored a slice of two US defence grants.

  • Craig Nolan
Boston is an exception in the biotech world. While other centres struggle, the city’s biotechs are performing strongly.

Riding the scariest rollercoaster on the ASX

If you thought crypto investors need to have strong stomachs, spare a thought for the investors who try their luck in the biotech sector.

  • William Bennett
This week’s Bulls N’ Bears ASX Runner of the Week is … Hydration Pharmaceuticals.

Hydration rehydrates share price with non-US asset sale

This week’s Bulls N’ Bears Runner of the Week is … Hydration Pharmaceuticals. The company sold its non-US assets for a sum five times its market capitalisation.

  • Craig Nolan
Novo Nordisk’s diabetes and weight-loss drugs, Ozempic and Wegovy, have soared to celebrity status.

It introduced Ozempic to the world. Now it must remake itself

Danish drugmaker Novo Nordisk has eclipsed French luxury group LVMH to become Europe’s most valuable company – thanks to demand for diabetes and weight-loss drugs.

  • Eshe Nelson

Original URL: https://www.theage.com.au/topic/biotechnology-5v0